“Semaglutide May Lower Heart Failure Hospitalization Risk in Obese Patients with Preserved Ejection Fraction, Study Suggests”

https://pubmed.ncbi.nlm.nih.gov/38118035

The study suggests that semaglutide, a glucagon-like peptide-1 receptor agonist, may reduce risk of heart failure hospitalization in obese patients with preserved ejection fraction.